AEGiS-IRIN: HIV/AIDS Brief

Important note: Information in this article was accurate in 2001. The state of the art may have changed since the publication date.

HIV/AIDS Brief

UN Integrated Regional Information Networks - September 7, 2001

AFRICA: Cipla's exports of AIDS drugs increase after discount offer Cipla, the Indian pharmaceutical firm that shook the global market last February when it offered to sell a generic three-drug AIDS therapy to Doctors Without Borders (MSF) for an annual cost of US $350 per patient, said on Tuesday that it was exporting the drugs to a "dozen" countries, including Nigeria, Algeria, Cameroon, Ivory Coast and Cambodia, and is in talks to expand its sales to other African and Southeast Asian nations, Reuters reported on Tuesday.

Sales of AIDS medications could increase to more than US $20 million a year if the South African government approves the company's request to export its drugs there, Cipla Chair Yusuf Hamied was reported as saying. He did not reveal the company's current sales figures for HIV/AIDS medications, but said that it is "gratifying that anti-AIDS medicines are finally beginning to reach those who need them desperately." The three-drug combination contains lamivudine, nevirapine and stavudine, whose patents are owned by GlaxoSmithKline, Boehringer-Ingelheim and Bristol-Myers Squibb.

Indian patent law applies only to the process used to make drugs, allowing generic drug makers like Cipla to produce patented medicines by retooling the production process. Cipla's offer, prompted some drug makers such as Bristol-Myers and Merck to offer developing nations additional price reductions. Last month, Cipla announced the reduction of prices of AIDS drugs in the country for the fourth time in the past nine months. The company lashed the prices by 39 percent.

For more information on Cipla go to: http://www.cipladoc.com/publications/aidswatch/aidsupdate.htm
010907
IR010914

Copyright © 2001 - Integrated Regional Information Networks (IRIN). Reproduction of this article (other than one copy for personal reference) must be cleared through the Integrated Regional Information Network. .

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.

Always watch for outdated information. This article first appeared in 2001. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980 – 2001. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .